Bringing live biotherapeutic products to the market is a complex process. It requires several years of development stages and represents an high entry barrier for many start-ups.
Richard Ellis, Head of Business Development at Biose, explains how CDMO companies like Biose assist start-up companies in this process by taking care of all the steps, thus becoming part of the microbiome revolution as well.
